Productivity in pharmaceutical–biotechnology R&D: the role of experience and alliances

Acemoglu, D., Linn, J., 2003. “Market Size in Innovation: Theory and Evidence From the Pharmaceutical Industry. National Bureau of Economic Research Paper 10038.

Arora, A., Gambardella, A., Pammolli, F., Riccaboni, M., 2000. The Nature and the Extent of the Market for Technology in Biopharmaceuticals, mimeo.

Carr, 1998, The Alchemists, The Economist

Cockburn, 2001, Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research, Journal of Health Economics, 20, 1033, 10.1016/S0167-6296(01)00108-4

DiMasi, 2003, The price of innovation: new estimates of drug development costs, Journal of Health Economics, 22, 151, 10.1016/S0167-6296(02)00126-1

DiMasi, 1991, Cost of innovation in the pharmaceutical industry, Journal of Health Economics, 10, 107, 10.1016/0167-6296(91)90001-4

DiMaisi, 2000, New Drug innovation and pharmaceutical industry structure: trends in the output of pharmaceutical firms, Drug Information Journal, 34, 1169, 10.1177/009286150003400425

DiMasi, 2001, Risks in new drug development: approval success rates for investigational drugs, Clinical Pharmacology & Therapeutics, 69, 297, 10.1067/mcp.2001.115446

Dranove, 1994, Do important drugs reach the market sooner?, Rand Journal of Economics, 25, 402, 10.2307/2555769

Henderson, 1996, Scale, scope, and spillovers: the determinants of research productivity in drug discovery, Rand Journal of Economics, 27, 32, 10.2307/2555791

Kogut, 1988, Joint ventures: theoretical and empirical perspectives, Strategic Management Journal, 9, 319, 10.1002/smj.4250090403

Lerner, J., Tsai, A., 2000. Do Equity Financing Cycles Matter? Evidence From Biotechnology Alliances, NBER Working Paper number 7464.

Lerner, 1988, The control of technological alliances: an empirical analysis of the biotechnology industry, The Journal of Industrial Economics, 46, 125, 10.1111/1467-6451.00066

Myers, 1984, Corporate financing and investment decisions when firms have information that investors do not have, Journal of Financial Economics, 13, 187, 10.1016/0304-405X(84)90023-0

Nicholson, S., Danzon, P.M., Jeffrey McCullough, 2003. Biotech-pharmaceutical alliances as a signal of asset and firm quality. Journal of Business, in press.

Pisano, G., 1997. R&D Performance, Collaborative Arrangements, and the Market-for-Know-How: A Test of the ‘Lemons’ Hypothesis in Biotechnology, mimeo.

Powell, 1992, Competitive cooperation in biotechnology: learning through networks?, 366

Powell, 1996, Interorganizational collaboration and the locus of innovation: networks of learning in biotechnology, Administrative Science Quarterly, 41, 116, 10.2307/2393988

Powell, 1999, Network position and firm performance: organizational returns to collaboration in the biotechnology industry

Pharmaceutical Research and Manufacturers of America. Pharmaceutical Industry Profile, 2001. PhRMA, Washington, DC. http://www.phrma.org/.